NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization181.5 mln
Float94.81 mln
Earnings Date08/11/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.58
Highly reliable
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.26
Very low leverage
ROE
-88.88
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Caribou Biosciences is a clinical-stage biotechnology company founded in 2011 and based in Berkeley, California. The company has developed a proprietary gene-editing platform that uses a hybrid RNA-DNA approach to modify donor-derived immune cells, allowing treatments to be manufactured in advance rather than tailored to each individual patient. Caribou is currently running two early-stage clinical trials testing these off-the-shelf cell therapies in patients with certain blood cancers, including aggressive lymphoma and multiple myeloma, who have not responded to prior treatment.
